GlaxoSmithKline Pharmaceuticals Intrinsic Value

GlaxoSmithKline Pharmaceuticals intrinsic value. GlaxoSmithKline Pharmaceuticals (GLAXO) median intrinsic value is ₹1124.26 from 10 valuation models (range ₹543–₹2280), vs current price ₹2713.40 — -58.6% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse GlaxoSmithKline Pharmaceutical shareholding analysis to track promoter, FII and institutional holdings.

Market Price (CMP)
₹2713.40
Primary Intrinsic Value
₹1745.04
Market Cap
₹458.6K Cr
-58.6% Downside
Median Value
₹1124.26
Value Range
₹543 - ₹2280
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%

GLAXO Valuation Methods Summary — DCF, Graham Number & P/E

GlaxoSmithKline Pharmaceuticals intrinsic value across 10 models vs current price ₹2713.40 — upside/downside and value range per method. Browse GLAXO cash flow statement for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1745.04 ₹1396.03 - ₹2094.05 -35.7% EPS: ₹79.32, Sector P/E: 22x
Book Value Method asset ₹542.68 ₹488.41 - ₹596.95 -80.0% Book Value/Share: ₹134.14, P/B: 2.0x
Revenue Multiple Method revenue ₹814.02 ₹732.62 - ₹895.42 -70.0% Revenue/Share: ₹297.28, P/S: 2.0x
EBITDA Multiple Method earnings ₹1124.26 ₹1011.83 - ₹1236.69 -58.6% EBITDA: ₹1900.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹1085.36 ₹868.29 - ₹1302.43 -60.0% CF Growth: 2.7%, Discount: 15%
PEG Ratio Method growth ₹814.02 ₹732.62 - ₹895.42 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹1225.49 ₹1102.94 - ₹1348.04 -54.8% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1356.70 ₹1221.03 - ₹1492.37 -50.0% ROE: 59.3%, P/E Multiple: 16x
Graham Defensive Method conservative ₹814.02 ₹732.62 - ₹895.42 -70.0% EPS: ₹79.32, BVPS: ₹134.14
Dividend Yield Method dividend ₹2280.00 ₹2052.00 - ₹2508.00 -16.0% DPS: ₹57.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

GLAXO Intrinsic Value vs Market Price — All Valuation Models

GlaxoSmithKline Pharmaceuticals fair value range ₹543–₹2280 vs current market price ₹2713.40 across 10 valuation models. For current market price and key ratios, visit GlaxoSmithKline Pharmaceutical share price today.

GLAXO Intrinsic Value Analysis — Undervalued or Overvalued?

GlaxoSmithKline Pharmaceuticals median intrinsic value ₹1124.26, current price ₹2713.40 — Trading Above Calculated Value by 58.6%, margin of safety -100.0%.

What is the intrinsic value of GLAXO?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of GlaxoSmithKline Pharmaceuticals (GLAXO) is ₹1124.26 (median value). With the current market price of ₹2713.40, this represents a -58.6% variance from our estimated fair value.

The valuation range spans from ₹542.68 to ₹2280.00, indicating ₹542.68 - ₹2280.00.

Is GLAXO undervalued or overvalued?

Based on our multi-method analysis, GlaxoSmithKline Pharmaceuticals (GLAXO) appears to be trading above calculated value by approximately 58.6%.

GLAXO Financial Health — Key Ratios vs Industry Benchmarks

GlaxoSmithKline Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 59.3% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 34.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 1.16x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

GLAXO Cash Flow Quality — Operating & Free Cash Flow

GlaxoSmithKline Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹903 Cr ₹903 Cr Positive Free Cash Flow 8/10
March 2025 ₹1,290 Cr ₹1,267 Cr Positive Free Cash Flow 8/10
March 2024 ₹582 Cr ₹582 Cr Positive Free Cash Flow 8/10
March 2023 ₹484 Cr ₹484 Cr Positive Free Cash Flow 8/10
March 2022 ₹811 Cr ₹608 Cr Positive Free Cash Flow 8/10